Drug Profile
Reteplase - Chiesi Farmaceutici
Alternative Names: CUSA-081Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Chiesi Farmaceutici
- Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Catheter thrombosis
Most Recent Events
- 10 Jul 2023 Chiesi Farmaceutici terminates the phase III READY 1 trial for Catheter thrombosis in Argentina, Belgium, Poland, Romania, Spain, USA and Czech Republic (Intraluminal), due to ongoing recruitment challenges and the decision was not based on any reported changes in the safety profile or any concerns with the anticipated efficacy profile (NCT03594175) (EudraCT2019-002124-32)
- 15 Apr 2022 Chiesi Farmaceutici withdraws phase III trial in Catheter thrombosis in Bulgaria, Hungary and in the US (NCT03992443)
- 22 Mar 2022 Reteplase is still in phase III trials for Catheter thrombosis in Argentina, Belgium, Poland, Romania, Spain, USA and Czech Republic (Intraluminal) (NCT03594175)